Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on cardiorenal function and treatment adherence: a prevalent new-user design study in tertiary hospitals

Sim, Ruth; Chong, Chun Wie; Loganadan, Navin Kumar; Adam, Noor Lita; Hussein, Zanariah; Lee, Shaun Wen Huey

doi:10.1093/rpsppr/rqad023

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our model also assumes the broad CKD population, and does not include subgroup analysis such as those with or without diabetes or those with or without heart failure. A higher cost savings is expected especially among those who have diabetes given the greater treatment effects [ 39 , 40 ]. Importantly, as there is a scarcity of information related to the disease transition matrix in Malaysia, data from the DAPA-CKD was used.…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness analysis of dapagliflozin for people with chronic kidney disease in Malaysia

Lim,

Lee

2024

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Introduction Chronic kidney disease (CKD) is a global health concern which results in significant economic burden. Despite this, treatment options are limited. Recently, dapagliflozin has been reported have benefits in people with CKD. This study aimed to evaluate the cost–effectiveness of dapagliflozin as an add-on to standard of care (SoC) in people with CKD in Malaysia. Methods A Markov model was adapted to estimate the economic and clinical benefits of dapagliflozin in people with Stage 2 to 5 CKD. The cost-effectiveness was performed based upon data from the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial supplemented with local costs and utility data whenever possible. Results In Malaysia, dapagliflozin in combination with SoC was the dominant intervention compared to SoC alone (RM 81,814 versus RM 85,464; USD19,762 vs USD20,644). Adding dapagliflozin to SoC in people with CKD increased life expectancy by 0.46 years and increased quality-adjusted life years (QALY) by 0.41 in comparison with SoC alone (10.01 vs. 9.55 years, 8.76 vs. 8.35 QALYs). This translates to a saving of RM8,894 (USD2,148) with every QALY gained. The benefits were due to the delay in CKD progression, resulting in lower costs of dialysis and renal transplantation. Results were robust to variations in assumptions over disease management costs as well as subgroup of population that would be treated and below the accepted willingness-to-pay thresholds of RM 46,000/QALY. Conclusion The use of dapagliflozin was projected to improved life expectancy and quality of life among people with CKD, with a saving RM8,894 (USD2,148) for every quality-adjusted life-year gained and RM7,898 (USD1,908) saving for every life year gained.

show abstract

Section: Discussionmentioning

confidence: 99%